PLEASANTON, Calif., Nov. 1, 2012 /PRNewswire/ -- Thoratec Corporation (THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the third quarter of 2012.
“Thoratec delivered excellent results during the third quarter, demonstrating continued momentum in the global VAD market as well as HeartMate II’s strong competitive position,” said Gary F. Burbach, President and Chief Executive Officer. “HeartMate II unit volume expanded by 27% during the third quarter and 23% for the first nine months of the year, driven by the U.S. Destination Therapy indication and healthy underlying trends in international markets,” he added.
